# PK/PD Investigation of Modufolin (Arfolitixorin) in Plasma, Tumor and Adjacent Mucosa Adjacent Mucosa in Patients With Colon Cancer

> **NCT01681472** · PHASE1,PHASE2 · COMPLETED · sponsor: **Isofol Medical AB** · enrollment: 32 (actual)

## Conditions studied

- Colonic Neoplasms

## Interventions

- **DRUG:** 6R-MTHF (arfolitixorin) 200 mg/m2
- **DRUG:** Levoleucovorin 200 mg/m2
- **DRUG:** 6R-MTHF (arfolitixorin) 60 mg/m2
- **DRUG:** Levoleucovorin 60 mg/m2

## Key facts

- **NCT ID:** NCT01681472
- **Lead sponsor:** Isofol Medical AB
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-09
- **Primary completion:** 2013-08
- **Final completion:** 2013-08
- **Target enrollment:** 32 (ACTUAL)
- **Last updated:** 2020-09-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01681472

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01681472, "PK/PD Investigation of Modufolin (Arfolitixorin) in Plasma, Tumor and Adjacent Mucosa Adjacent Mucosa in Patients With Colon Cancer". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01681472. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*